1. In Vivo
  2. >>Innovation

Amir Belson: Stealth Medtech Entrepreneur

Amir Belson is among the most prolific device entrepreneurs in the industry today, having launched a dozen companies in the past 12 years. Not as well-known as other physician-inventors, he combines an aggressive IP strategy with an innovative approach to early-stage financing to launch companies in a variety of clinical spaces.

While good ideas alone are not enough to make a successful device entrepreneur, they are an essential place to start. And when you are a physician-inventor who can seemingly generate an endless supply of your own ideas, so much the better. That describes Amir Belson, MD, in a nutshell. When the Israeli-trained physician came to the US to do a fellowship at Stanford, he had 64 ideas for inventions jotted down in tiny Hebrew letters on a single sheet of paper.

Since the early 2000s, Belson has translated his natural inventiveness into a successful company creation model that has produced a dozen medtech start-ups in a wide variety of clinical areas....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.